(VIANEWS) – iRadimed Corporation (IRMD), Rollins (ROL), Assertio Holdings (ASRT) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. iRadimed Corporation (IRMD)
14.6% sales growth and 21.77% return on equity
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Earnings Per Share
As for profitability, iRadimed Corporation has a trailing twelve months EPS of $1.19.
PE Ratio
iRadimed Corporation has a trailing twelve months price to earnings ratio of 32.72. Meaning, the purchaser of the share is investing $32.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.77%.
Volume
Today’s last reported volume for iRadimed Corporation is 22486 which is 37.27% below its average volume of 35846.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 24.1% and 12.5%, respectively.
2. Rollins (ROL)
12.2% sales growth and 31.48% return on equity
Rollins, Inc., through its subsidiaries, provides pest and wildlife control services to residential and commercial customers in the United States and internationally. The company offers pest control services to residential properties protecting from common pests, including rodents, insects, and wildlife. It also provides workplace pest control solutions for customers across various end markets, such as healthcare, foodservice, and logistics. In addition, the company offers termite protection services and ancillary services. It serves clients directly, as well as through franchisee operations. Rollins, Inc. was incorporated in 1948 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, Rollins has a trailing twelve months EPS of $0.79.
PE Ratio
Rollins has a trailing twelve months price to earnings ratio of 46.24. Meaning, the purchaser of the share is investing $46.24 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.48%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 8, 2023, the estimated forward annual dividend rate is 0.52 and the estimated forward annual dividend yield is 1.45%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Rollins’s EBITDA is 117.07.
3. Assertio Holdings (ASRT)
11.1% sales growth and 51.07% return on equity
Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company's pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, an NSAID for relief of mild to moderate acute pain; and SPRIX, an NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
Earnings Per Share
As for profitability, Assertio Holdings has a trailing twelve months EPS of $1.71.
PE Ratio
Assertio Holdings has a trailing twelve months price to earnings ratio of 1.44. Meaning, the purchaser of the share is investing $1.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 51.07%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Assertio Holdings’s EBITDA is 14.13.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 37.5% and a drop 94.8% for the next.
Sales Growth
Assertio Holdings’s sales growth is 69.5% for the current quarter and 11.1% for the next.
4. Royalty Pharma (RPRX)
10.8% sales growth and 4.66% return on equity
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Earnings Per Share
As for profitability, Royalty Pharma has a trailing twelve months EPS of $0.57.
PE Ratio
Royalty Pharma has a trailing twelve months price to earnings ratio of 49.31. Meaning, the purchaser of the share is investing $49.31 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.66%.
Yearly Top and Bottom Value
Royalty Pharma’s stock is valued at $28.10 at 11:22 EST, way under its 52-week high of $44.47 and above its 52-week low of $25.92.
5. Axalta Coating Systems Ltd. (AXTA)
7.1% sales growth and 14.95% return on equity
Axalta Coating Systems Ltd., through its subsidiaries, manufactures, markets, and distributes high-performance coatings systems in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It operates through two segments, Performance Coatings and Transportation Coatings. The company offers water and solvent borne products and systems to repair damaged vehicles for independent body shops, multi-shop operators, and original equipment manufacturer (OEM) dealership body shops. It also provides functional and decorative liquid and powder coatings used in various industrial applications, including architectural cladding and fittings, automotive coatings, general industrial, job coaters, electrical insulation coatings, HVAC, appliances, industrial wood, coil, rebar, and oil and gas pipelines; and wood coatings for building product, cabinet, flooring, and furniture markets under the Voltatex, AquaEC, Durapon, Hydropon, UNRIVALED, Tufcote, and Ceranamel for liquid coatings; and Alesta, Nap-Gard, Abcite, and Plascoat brands for powder coatings. In addition, the company develops and supplies electrocoat, primer, basecoat, and clearcoat products for OEMs of light and commercial vehicles; and various coatings systems for various commercial applications, including HDT, bus, and rail under the Imron, Imron Elite, Centari, Rival, Corlar epoxy undercoats, and AquaEC brands; and sells and ships its products to light vehicle OEM customers. It also sells its product under the Audurra, Challenger, Chemophan, ColorNet, Cromax, Cromax Mosaic, Durapon 70, Duxone, Harmonized Coating Technologies, Imron ExcelPro, Lutophen, Nason, Spies Hecker, Standox, Stollaquid, Syntopal, Syrox, and Vermeera brand names. The company was formerly known as Axalta Coating Systems Bermuda Co., Ltd. and changed its name to Axalta Coating Systems Ltd. in August 2014. Axalta Coating Systems Ltd. was founded in 1866 and is headquartered in Philadelphia, Pennsylvania.
Earnings Per Share
As for profitability, Axalta Coating Systems Ltd. has a trailing twelve months EPS of $1.05.
PE Ratio
Axalta Coating Systems Ltd. has a trailing twelve months price to earnings ratio of 26.43. Meaning, the purchaser of the share is investing $26.43 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.95%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.8%, now sitting on 5.05B for the twelve trailing months.
Yearly Top and Bottom Value
Axalta Coating Systems Ltd.’s stock is valued at $27.75 at 11:22 EST, way under its 52-week high of $33.68 and way above its 52-week low of $20.66.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Axalta Coating Systems Ltd.’s EBITDA is 53.3.
Volume
Today’s last reported volume for Axalta Coating Systems Ltd. is 3104760 which is 35.12% above its average volume of 2297700.
6. Stantec (STN)
7% sales growth and 13.54% return on equity
Stantec Inc. provides e professional services in the areas of infrastructure and facilities to the public and private sectors clients in Canada, the United States, and internationally. The company provides consulting services in engineering, architecture, interior design, landscape architecture, surveying, environmental sciences, project management, and project economics. It also offers planning and design consulting services to clients in residential, logistics, retail, infrastructure, energy, higher education, and urban regeneration sectors; architectural and interior design, and planning services in the science and technology, commercial workplace, higher education, residential, and hospitality markets. In addition, it provides transportation planning and engineering services; project delivery consultancy services for mining, resources, and industrial infrastructure projects; and paleontological and archaeological services for the rail, transportation, water, and power and energy sectors. Further, the company offers environmental and cultural resource compliance services, as well as serves science and technology, commercial workplace, higher education, residential, and hospitality markets. Additionally, it is involved in the design, development, and delivery of sustainable projects; and design, construction administration, commissioning, maintenance, decommissioning, and remediation activities. The company was formerly known as Stanley Technology Group Inc. and changed its name to Stantec Inc. in October 1998. Stantec Inc. was founded in 1954 and is headquartered in Edmonton, Canada.
Earnings Per Share
As for profitability, Stantec has a trailing twelve months EPS of $1.95.
PE Ratio
Stantec has a trailing twelve months price to earnings ratio of 33.68. Meaning, the purchaser of the share is investing $33.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.54%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Sep 27, 2023, the estimated forward annual dividend rate is 0.57 and the estimated forward annual dividend yield is 0.87%.
